HMI-115: Novel Endometriosis Drug Allows Pregnancy During Treatment
Key Insights
HMI-115, a new drug for endometriosis (search), significantly reduces pain and uniquely allows patients to become pregnant during treatment.
The drug works by blocking a protein produced in response to endometriosis (search), addressing a long-standing need for hormone-bypassing pain relief.
In trials, HMI-115 reduced pain levels by an average of 42% without disrupting the menstrual cycle, offering a significant advantage over existing therapies.
A novel drug, HMI-115, offers new hope for women with endometriosis (search) who wish to conceive. Developed by Hope Medicine (search), the drug not only alleviates the debilitating pain associated with the condition but also allows patients to pursue pregnancy during treatment, a significant advancement over existing therapies.
Endometriosis (search), affecting approximately one in ten women, occurs when tissue similar to the uterine lining grows outside the uterus, leading to bleeding, inflammation, and potential infertility. Current treatments often preclude pregnancy, presenting a difficult choice for women desiring children.
Mechanism of Action
HMI-115 functions by inhibiting the production of a specific protein triggered by endometriosis (search), which is believed to be responsible for the pain experienced by patients. This targeted approach avoids the disruption of sex hormones, a common side effect of other endometriosis drugs like relugolix, which, while effective in reducing symptoms, prevents pregnancy by disrupting the menstrual cycle.
Clinical Trial Results
Clinical trials of HMI-115 have demonstrated promising results, with an average pain reduction of 42%. Crucially, the drug did not appear to disrupt the menstrual cycle, offering a pathway to pregnancy for women undergoing treatment. Professor Rui-Ping Xiao, leading the research at Tsinghua University in Shanghai, emphasized the significance of this development, stating, "For the past 40 years, people have been calling for a new target that provides pain relief while bypassing sex hormones – we are answering that call."
Future Development
Hope Medicine (search) is preparing to launch a larger global trial to further evaluate the efficacy and safety of HMI-115. This expansion reflects the urgent need for innovative endometriosis (search) treatments, as many patients endure diagnostic delays, waiting an average of eight years from symptom onset to diagnosis. Recent NHS guidance has urged GPs to expedite hospital referrals for women with suspected endometriosis to address the issue of missed or delayed diagnoses.